Literature DB >> 26056016

Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism.

Mazhar Müslüm Tuna1, Mustafa Çalışkan2, Mustafa Ünal3, Taner Demirci2, Berçem Ayçiçek Doğan3, Kerim Küçükler4, Mustafa Özbek2, Dilek Berker3, Tuncay Delibaşı2, Serdar Güler4.   

Abstract

Normocalcemic primary hyperparathyroidism (NC-PHPT) is a variant of hyperparathyroidism, characterized by normal serum calcium levels, high parathyroid hormone (PTH) and normal 25-OH vitamin D status. The present study aimed to compare complications related to hyperparathyroidism in patients with NC-PHPT and hypercalcemic PHPT (HC-PHPT). We retrospectively evaluated the records of 307 PHPT patients between January 2010 and March 2013. We excluded patients with impaired renal function and liver failure. All patients underwent a biochemical and hormonal examination including serum glucose, albumin, total calcium, phosphorus, creatinine, lipoproteins, PTH and 25-OH vitamin D. Nephrolithiasis and bone mineral density were documented based on a review of the medical records. The study population consisted of 36 (12 %) males and 271 (88 %) females with a mean age of 53.3 ± 9.5 years (29-70 years). Twenty-three of the patients were diagnosed with NC-PHPT (group 1) and 284 were diagnosed with HC-PHPT (group 2). There were no significant differences in terms of age, gender, prevalence of hypertension, low bone mineral density and kidney stones between the groups. The mean thyroid-stimulating hormone (TSH) and low-density lipoprotein (LDL) levels were significantly higher in group 1 than in group 2. Our study found that patients with NC-PHPT have similar several complications as patients with HC-PHPT. NC-PHPT patients have higher TSH levels despite being within the normal range, and higher LDL-C levels than patients with HC-PHPT. However, this relationship needs to be clarified in future studies with larger cohorts.

Entities:  

Keywords:  Kidney stones; Normocalcemia; Osteoporosis; Parathormone; Primary hyperparathyroidism

Mesh:

Substances:

Year:  2015        PMID: 26056016     DOI: 10.1007/s00774-015-0673-3

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  17 in total

1.  Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening.

Authors:  Emil Hagström; Ewa Lundgren; Jonas Rastad; Per Hellman
Journal:  Eur J Endocrinol       Date:  2006-07       Impact factor: 6.664

2.  Epidemiology of primary hyperparathyroidism in Europe.

Authors:  Silvano Adami; Claudio Marcocci; Davide Gatti
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

Review 3.  Normocalcemic primary hyperparathyroidism.

Authors:  Natalie E Cusano; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

4.  Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men.

Authors:  Eric Orwoll; Janet Babich Blank; Elizabeth Barrett-Connor; Jane Cauley; Steven Cummings; Kristine Ensrud; Cora Lewis; Peggy M Cawthon; Robert Marcus; Lynn M Marshall; Joan McGowan; Kathy Phipps; Sherry Sherman; Marcia L Stefanick; Katie Stone
Journal:  Contemp Clin Trials       Date:  2005-10       Impact factor: 2.226

5.  Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism.

Authors:  Ilkay Cakir; Kursad Unluhizarci; Fatih Tanriverdi; Gulsah Elbuken; Zuleyha Karaca; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2012-02-12       Impact factor: 3.633

6.  Low basal thyrotropin with normal thyroid function in primary hyperparathyroidism.

Authors:  C Gillet; P Bergmann; D Francois; J J Body; J Corvilain
Journal:  Acta Endocrinol (Copenh)       Date:  1989-11

7.  Is there a link between Hashimoto's thyroiditis and primary hyperparathyroidism? A study of serum parathormone and anti-TPO antibodies in 2267 patients.

Authors:  Vesna D Ignjatovic; Milovan D Matovic; Vladimir R Vukomanovic; Slobodan M Jankovic; Radan R Džodić
Journal:  Hell J Nucl Med       Date:  2013 May-Aug       Impact factor: 1.102

8.  "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease.

Authors:  Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

9.  Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.

Authors:  H Lowe; D J McMahon; M R Rubin; J P Bilezikian; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

10.  Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: More Stone than Bone?

Authors:  L M Amaral; D C Queiroz; T F Marques; M Mendes; F Bandeira
Journal:  J Osteoporos       Date:  2012-03-25
View more
  12 in total

1.  CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update.

Authors:  Marie Dion; Ghada Ankawi; Ben Chew; Ryan Paterson; Nabil Sultan; Patti Hoddinott; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

Review 2.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 3.  Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm.

Authors:  Joaquín Gómez-Ramírez; Radu Mihai
Journal:  Langenbecks Arch Surg       Date:  2017-08-19       Impact factor: 3.445

4.  Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men.

Authors:  Emma O Billington; Greg D Gamble; Ian R Reid
Journal:  Bonekey Rep       Date:  2016-12-07

5.  PRIMARY HYPERPARATHYROIDISM DETECTED BY PARATHYROID INCIDENTALOMA: CLINICAL FEATURES, WORK-UP AND MANAGEMENT.

Authors:  V Pandzic Jaksic; A Majic; T Rezic; J Andric; O Jaksic; A Zrilic; S Marusic
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

6.  How useful is an oral calcium load test for diagnosing recurrent calcium stone formers?

Authors:  Isabelle N Tostivint; Vincent Castiglione; Rana Alkouri; Jean Philippe Bertocchio; Rachida Inaoui; Michel Daudon; Marie-Paule Dousseaux; Etienne Cavalier; Laurence Pieroni; Hassan Izzedine
Journal:  Urolithiasis       Date:  2022-08-22       Impact factor: 2.861

7.  UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.

Authors:  Naeem Bhojani; Jennifer Bjazevic; Brendan Wallace; Linda Lee; Kamaljot S Kaler; Marie Dion; Andrea Cowan; Nabil Sultan; Ben H Chew; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

Review 8.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

Review 9.  Normocalcaemic primary hyperparathyroidism: what is the role of parathyroid surgery?

Authors:  Nivaran Aojula; Shahab Khan; Neil Gittoes; Zaki Hassan-Smith
Journal:  Ther Adv Endocrinol Metab       Date:  2021-02-27       Impact factor: 3.565

Review 10.  Physical Activity-Dependent Regulation of Parathyroid Hormone and Calcium-Phosphorous Metabolism.

Authors:  Giovanni Lombardi; Ewa Ziemann; Giuseppe Banfi; Sabrina Corbetta
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.